An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects (6 to < 18 Years Old) With Severe Plaque Psoriasis
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Brodalumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Bausch Health Companies; Ortho Dermatologics
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 02 May 2018 Planned End Date changed from 15 Jun 2019 to 15 Sep 2019.
- 02 May 2018 Planned primary completion date changed from 15 Jan 2019 to 15 Apr 2019.